Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments

References

• FDA approved Drug Products [webpage on the Internet]Silver SpringU.S. Food and Drug Administration Available from: http://www.accessdata.fda.gov/Scripts/cder/drugsatfda/index.cfmAccessed May 21, 2014
   Google Scholar
• ACC/AHA Joint GuidelinesDallasAmerican Heart Association2014 Available from: http://my.americanheart.org/professional/StatementsGuidelines/ByTopic/TopicsA-C/ACCAHA-Joint-Guidelines_UCM_321694_Article.jspAccessed July 27, 2014
   Google Scholar
• LijferingWMFlintermanLEVandenbrouckeJPRosendaalFRCannegieterSCRelationship between venous and arterial thrombosis: a review of the literature from a causal perspectiveSemin Thromb Hemost201137888589622198853
   PubMed Web of Science ®Google Scholar
• SpbieszcykPFishbeinMCGoldhaberSZAcute pulmonary embolism. don’t ignore the plateletCirculation20021061748174912356622
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSREffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• ChenZMJiangLXChenYPAddition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trialLancet200536694971607162116271642
   PubMed Web of Science ®Google Scholar
• CURRENT-OASIS 7 InvestigatorsMehtaSRBassandJPDose comparisons of clopidogrel and aspirin in acute coronary syndromesN Engl J Med20103631093094220818903
   PubMed Web of Science ®Google Scholar
• PattiGColonnaGPasceriVPepeLLMontinaroADi SciascioGRandomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) studyCirculation2005111162099210615750189
   PubMed Web of Science ®Google Scholar
• DangasGMehranRGuagliumiGRole of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trialJ Am Coll Cardiol200954151438144619796737
   PubMed Web of Science ®Google Scholar
• Siller-MatulaJMHuberKChristGImpact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisHeart2011979810520736210
   PubMedGoogle Scholar
• von BeckerathNTaubertDPogatsa-MurrayGSchömigEKastratiASchömigAAbsorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) TrialCirculation2005112192946295016260639
   PubMed Web of Science ®Google Scholar
• MontalescotGSiderisGMeulemanCA randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trialJ Am Coll Cardiol200648593193816949482
   PubMed Web of Science ®Google Scholar
• SerebruanyVLSteinhublSRBergerPBMalininAIBhattDLTopolEJVariability in platelet responsiveness to clopidogrel among 544 individualsJ Am Coll Cardiol200545224625115653023
   PubMed Web of Science ®Google Scholar
• HagiharaKKazuiMKuriharaAA possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrelDrug Metab Dispos200937112145215219704027
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost20075122429243617900275
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopi-dogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• BrandtJTPayneCDWiviottSDA comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAm Heart J2007153166.e9e1617174640
   PubMed Web of Science ®Google Scholar
• JernbergTPayneCDWintersKJPrasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEur Heart J200627101166117316621870
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPButlerKRandomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET studyCirculation2009120252577258519923168
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPButlerKResponse to ticagrelor in clopi-dogrel nonresponders and responders and effect of switching therapies: the RESPOND studyCirculation2010121101188119920194878
   PubMed Web of Science ®Google Scholar
• ArmstrongDSummersCEwartLNylanderSSidawayJEvan GiezenJJCharacterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1J Cardiovasc Pharmacol Ther201419220921924414167
   PubMed Web of Science ®Google Scholar
• SchulzSAngiolilloDJAntoniucciDRandomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy – design and rationale of the iNtracoro-nary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trialJ Cardiovasc Transl Res2014719110024371012
   PubMed Web of Science ®Google Scholar
• AlexopoulosDGalatiAXanthopoulouITicagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic studyJ Am Coll Cardiol201260319319922789884
   PubMed Web of Science ®Google Scholar
• O’GaraPTKushnerFGAscheimDD2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation2013127e362e42523247304
   PubMed Web of Science ®Google Scholar
• YendeSWunderinkRGEffect of clopidogrel on bleeding after coronary artery bypass surgeryCrit Care Med200129122271227511801823
   PubMed Web of Science ®Google Scholar
• HongoRHLeyJDickSEYeeRRThe effect of clopidogrel in combination with aspirin when given before coronary artery bypass graftingJ Am Coll Cardiol200240223123712106925
   PubMed Web of Science ®Google Scholar
• AntmanEMHandMArmstrongPW2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing CommitteeCirculation2008117229632918071078
   PubMed Web of Science ®Google Scholar
• KapetanakisEIMedlamDABoyceSWClopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist’s panacea or the surgeon’s headache?Eur Heart J200526657658315723815
   PubMed Web of Science ®Google Scholar
• ZeymerUArntzHRMarkBEfficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trialClin Res Cardiol2012101430531222186968
   PubMed Web of Science ®Google Scholar
• SadanandanSCannonCPGibsonCMA risk score to estimate the likelihood of coronary artery bypass surgery during the index hos-pitalization among patients with unstable angina and non-ST-segment elevation myocardial infarctionJ Am Coll Cardiol200444479980315312862
   PubMed Web of Science ®Google Scholar
• FitchettDEikelboomJFremesSDual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular SocietyCan J Cardiol20092512683689 English; French19960127
   PubMed Web of Science ®Google Scholar
• MarchiniJMorrowDResnicFAn algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary interventionCrit Pathw Cardiol20109419219821119336
   PubMedGoogle Scholar
• MontalescotGBarraganPWittenbergOPlatelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionN Engl J Med2001344251895190311419426
   PubMed Web of Science ®Google Scholar
• AntoniucciDMiglioriniAParodiGAbciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting aloneCirculation2004109141704170615066943
   PubMed Web of Science ®Google Scholar
• EllisSGTenderaMde BelderMAFacilitated PCI in patients with ST-elevation myocardial infarctionN Engl J Med2008358212205221718499565
   PubMed Web of Science ®Google Scholar
• De LucaGNavareseEMarinoPRisk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trialsEur Heart J200930222705271319875386
   PubMed Web of Science ®Google Scholar
• Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)StegPGJamesSKESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEur Heart J201233202569261922922416
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJNeumannFJAbciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trialJAMA2006295131531153816533938
   PubMed Web of Science ®Google Scholar
• KakkarAKMoustaphaAHanleyHGComparison of intracoro-nary vs intravenous administration of abciximab in coronary stentingCatheter Cardiovasc Interv2004611313414696156
   PubMed Web of Science ®Google Scholar
• HansenPRIversenAAbdullaJImproved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysisJ Invasive Cardiol201022627828220516508
   PubMed Web of Science ®Google Scholar
• BertrandOFRodés-CabauJLaroseEIntracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized studyAm J Cardiol2010105111520152720494655
   PubMed Web of Science ®Google Scholar
• LevineGNBatesERBlankenshipJC2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventionsCirculation2011124e574e65122064601
   PubMed Web of Science ®Google Scholar
• GurmHSTamhaneUMeierPGrossmanPMChetcutiSBatesERA comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trialsCirc Cardiovasc Interv20092323023620031720
   PubMed Web of Science ®Google Scholar
• SciricaBMBonacaMPBraunwaldEVorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialLancet201238098501317132422932716
   PubMed Web of Science ®Google Scholar
• FareedJHoppensteadtDWalengaJPharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practiceClin Pharmacokinet200342121043105712959635
   PubMed Web of Science ®Google Scholar
• FergusonJJCaliffRMAntmanEMEnoxaparin vs unfraction-ated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJAMA20042921455415238590
   PubMed Web of Science ®Google Scholar
• CohenMMahaffeyKWPieperKA subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesJ Am Coll Cardiol20064871346135417010793
   PubMed Web of Science ®Google Scholar
• MontalescotGZeymerUSilvainJIntravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialLancet2011378979269370321856483
   PubMed Web of Science ®Google Scholar
• MontalescotGGalloRWhiteHDEnoxaparin versus unfrac-tionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in per-cutaneous coronary intervention patients, an international randomized evaluation) trialJACC Cardiovasc Interv20092111083109119926048
   PubMed Web of Science ®Google Scholar
• KleinWBuchwaldAHillisSEComparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)Circulation199796161689236418
   PubMed Web of Science ®Google Scholar
• KatsourasCMichalisLKPapamichaelNEnoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 monthsAm Heart J2005150338539116169312
   PubMed Web of Science ®Google Scholar
• StoneGWWhiteHDOhmanEMBivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trialLancet2007369956590791917368152
   PubMed Web of Science ®Google Scholar
• StoneGWWitzenbichlerBGuagliumiGBivalirudin during primary PCI in acute myocardial infarctionN Engl J Med2008358212218223018499566
   PubMed Web of Science ®Google Scholar
• StegPGvan ‘t HofAHammCWBivalirudin started during emergency transport for primary PCIN Engl J Med2013369232207221724171490
   PubMed Web of Science ®Google Scholar
• SchulzSRichardtGLaugwitzKLPrasugrel plus bivalirudin vs clopidogrel plus heparin in patients with ST-segment elevation myocardial infarctionEur Heart J201435342285229424816809
   PubMed Web of Science ®Google Scholar
• ShahzadAKempIMarsCUnfractionated heparin versus bivali-rudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trialLancet2014
   PubMedGoogle Scholar
• YusufSMehtaSRChrolaviciusSEffects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialJAMA2006295131519153016537725
   PubMed Web of Science ®Google Scholar
• SinnaevePRAdriaenssensTHöchtlTHuberKNew oral anticoagulant agents after ACSEur Heart J Acute Cardiovasc Care201211879324062894
   PubMedGoogle Scholar
• MegaJLBraunwaldEWiviottSDRivaroxaban in patients with a recent acute coronary syndromeN Engl J Med2012366191922077192
   PubMed Web of Science ®Google Scholar
• Rivaroxaban STEMI study hits print as FDA delivers setback: ATLAS ACS 2-TIMI 51 [article on the Internet]Medscape; WebMD LLC3052013 Available from: http://www.medscape.com/viewarticle/791479Accessed July 27, 2014
   Google Scholar
• AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med2011365869970821780946
   PubMed Web of Science ®Google Scholar
• OldgrenJBudajAGrangerCBDabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEur Heart J201132222781278921551462
   PubMed Web of Science ®Google Scholar
• ReedGWCannonCPTriple oral antithrombotic therapy in atrial fibrillation and coronary artery stentingClin Cardiol2013361058559423873635
   PubMed Web of Science ®Google Scholar
• DewildeWJOirbansTVerheugtFWUse of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialLancet201338198721107111523415013
   PubMed Web of Science ®Google Scholar
• DewildeWJJanssenPWKelderJCUninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trialEuroIntervention2014pii:20140202–08
   Google Scholar
• JanuaryCTWannLSAlpertJS2014AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyCirculation Epub2014410
   Google Scholar
• Janssen Scientific Affairs, LLCA Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59–7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) Available from: http://clinicaltrials.gov/show/NCT01830543. NLM identifier: NCT01830543Accessed July 27, 2014
   Google Scholar
• BhattDLLincoffAMGibsonCMIntravenous platelet blockade with cangrelor during PCIN Engl J Med2009361242330234119915222
   PubMed Web of Science ®Google Scholar
• HarringtonRAStoneGWMcNultySPlatelet inhibition with cangrelor in patients undergoing PCIN Engl J Med2009361242318232919915221
   PubMed Web of Science ®Google Scholar
• BhattDLStoneGWMahaffeyKWEffect of platelet inhibition with cangrelor during PCI on ischemic eventsN Engl J Med2013368141303131323473369
   PubMed Web of Science ®Google Scholar
• FDA Advisory Panel Votes No on Approving Cangrelor for PCI, Bridge Therapy [article on the Internet]Medscape; WebMD LLC2122014 Available from: http://www.medscape.com/viewarticle/820567Accessed July 27, 2014
   Google Scholar
• SteinhublSROhJJOestreichJHFerrarisSCharnigoRAkersWSTransitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effectThromb Res2008121452753417631948
   PubMed Web of Science ®Google Scholar
• WelshRCRaoSVZeymerUA randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trialCirc Cardiovasc Interv20125333634622647518
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFirstenbergMSPriceMJBridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trialJAMA2012307326527422253393
   PubMed Web of Science ®Google Scholar
• RaoSVMelloniCMyles-DimauroSEvaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) TrialCirculation2010121151713172120368520
   PubMed Web of Science ®Google Scholar
• CohenMGPurdyDARossiJSFirst clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionCirculation2010122661462220660806
   PubMed Web of Science ®Google Scholar
• Regado Biosciences, IncA Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate) Available from: http://clinicaltrials.gov/show/NCT01848106. NLM identifier: NCT01848106Accessed July 27, 2014
   Google Scholar